1. |
Golpe R, Suárez-Valor M, Martín-Robles I, et al. Mortality in COPD patients according to clinical phenotypes. Int J Chron Obstruct Pulmon Dis, 2018, 13: 1433-1439.
|
2. |
Hernández Vázquez J, Ali García I, Jiménez-García R, et al. COPD phenotypes: Differences in survival. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2245-2251.
|
3. |
DeMarco B, MacRosty CR. Bronchoscopic management of COPD and advances in therapy. Life (Basel), 2023, 13(4): 1036.
|
4. |
Li R, Shi J, Huang D, et al. Preoperative risk factors for successful extubation or not after lung transplantation. J Thorac Dis, 2020, 12(12): 7135-7144.
|
5. |
Hartman JE, Garner JL, Shah PL, et al. New bronchoscopic treatment modalities for patients with chronic bronchitis. Eur Respir Rev, 2021, 30(159): 200281.
|
6. |
Perotin JM, Dewolf M, Launois C, et al. Bronchoscopic management of asthma, COPD and emphysema. Eur Respir Rev, 2021, 30(159): 200029.
|
7. |
Brantigan OC, Mueller E, Kress MB. A surgical approach to pulmonary emphysema. Am Rev Respir Dis, 1959, 80(1, Part 2): 194-206.
|
8. |
Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg, 1995, 109(1): 106-116.
|
9. |
Ware JH. The National emphysema treatment trial: How strong is the evidence? N Engl J Med, 2003, 348(21): 2055-2056.
|
10. |
Emery MJ, Couëtil LL, Coad J, et al. Lung volume reduction (LVR) by bronchoscopic thermal vapor ablation (BTVA). Chest, 2007, 132(4): 439B.
|
11. |
Emery MJ, Eveland RL, Eveland K, et al. Lung volume reduction by bronchoscopic administration of steam. Am J Respir Crit Care Med, 2010, 182(10): 1282-1291.
|
12. |
Tuck SA, Lopes-Berkas V, Beam S, et al. Bronchoscopic thermal vapor ablation in a canine model of emphysema. Int J Chron Obstruct Pulmon Dis, 2012, 7: 21-31.
|
13. |
Snell GI, Hopkins P, Westall G, et al. A feasibility and safety study of bronchoscopic thermal vapor ablation: A novel emphysema therapy. Ann Thorac Surg, 2009, 88(6): 1993-1998.
|
14. |
Shah PL, Gompelmann D, Valipour A, et al. Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results. Lancet Respir Med, 2016, 4(9): e44-e45.
|
15. |
Herth FJ, Valipour A, Shah PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med, 2016, 4(3): 185-193.
|
16. |
Zhu W, Zhang Y, Herth FJF, et al. Efficacy of bronchoscopic thermal vapor ablation in patients with heterogeneous emphysema and lobar quantification by three-dimensional ventilation/perfusion single-photon emission computed tomography/computed tomography: A prospective pilot study from China. Chin Med J (Engl), 2022, 135(17): 2098-2100.
|
17. |
Danek CJ, Lombard CM, Dungworth DL, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol (1985), 2004, 97(5): 1946-1953.
|
18. |
Miller JD, Cox G, Vincic L, et al. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest, 2005, 127(6): 1999-2006.
|
19. |
Cox G, Miller JD, McWilliams A, et al. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med, 2006, 173(9): 965-969.
|
20. |
Wang Y, Xu J, Meng Y, et al. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3341-3348.
|
21. |
Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol, 2009, 4: 435-459.
|
22. |
Wang T, Fu P, Long F, et al. Research on the effectiveness and safety of bronchial thermoplasty in patients with chronic obstructive pulmonary disease. Eur J Med Res, 2023, 28(1): 331.
|
23. |
Godwin BL, Coad JE. Healing responses following cryothermic and hyperthermic tissue ablation. Proc Spie, 2009, 7181.
|
24. |
Coad JE, Bischof JC. Histologic differences between cryothermic and hyperthermic therapies. Proceedings of SPIE-The International Society for Optical Engineering, 2003, 4954: 27-36.
|
25. |
Allington HV. Liquid nitrogen in the treatment of skin diseases. Calif Med, 1950, 72(3): 153-155.
|
26. |
Pasricha PJ, Hill S, Wadwa KS, et al. Endoscopic cryotherapy: Experimental results and first clinical use. Gastrointest Endosc, 1999, 49(5): 627-631.
|
27. |
Krimsky WS, Broussard JN, Sarkar SA, et al. Bronchoscopic spray cryotherapy: Assessment of safety and depth of airway injury. J Thorac Cardiovasc Surg, 2010, 139(3): 781-782.
|
28. |
Slebos DJ, Breen D, Coad J, et al. Safety and histological effect of liquid nitrogen metered spray cryotherapy in the lung. Am J Respir Crit Care Med, 2017, 196(10): 1351-1352.
|
29. |
Garner JL, Shaipanich T, Hartman JE, et al. A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD. Eur Respir J, 2020, 56(6): 2000556.
|
30. |
Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res, 2006, 7(1): 73.
|
31. |
Hummel JP, Mayse ML, Dimmer S, et al. Physiologic and histopathologic effects of targeted lung denervation in an animal model. J Appl Physiol (1985), 2019, 126(1): 67-76.
|
32. |
Slebos DJ, Klooster K, Koegelenberg CF, et al. Targeted lung denervation for moderate to severe COPD: A pilot study. Thorax, 2015, 70(5): 411-419.
|
33. |
Valipour A, Shah PL, Pison C, et al. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. Respiration, 2019, 98(4): 329-339.
|
34. |
Valipour A, Shah PL, Herth FJ, et al. Two-year outcomes for the double-blind, randomized, sham-controlled study of targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2. Int J Chron Obstruct Pulmon Dis, 2020, 15: 2807-2816.
|
35. |
Conway F, Tonkin J, Valipour A, et al. Crossover patient outcomes for targeted lung denervation in moderate to severe chronic obstructive pulmonary disease: AIRFLOW-2. Respiration, 2022, 101(11): 1069-1074.
|
36. |
Pison C, Shah PL, Slebos DJ, et al. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. Respir Res, 2021, 22(1): 62.
|
37. |
Hartman JE, Conway F, Degano B, et al. Rate of lung function decline slows in the 3 years after targeted lung denervation in COPD. Respir Med, 2021, 188: 106604.
|
38. |
Vikingstad EM, de Ridder GG, Glisson RR, et al. Comparison of acute histologic and biomechanical effects of radiofrequency ablation and cryoablation on periarticular structures in a swine model. J Vasc Interv Radiol, 2015, 26(8): 1221-1228.
|
39. |
Wang K, Sun J, Gao W, et al. Feasibility, effectiveness, and safety of a novel cryo-balloon targeted lung denervation technique in an animal model. Cryobiology, 2020, 93: 27-32.
|
40. |
Valipour A, Fernandez-Bussy S, Ing AJ, et al. Bronchial rheoplasty for treatment of chronic bronchitis. Twelve-month results from a multicenter clinical trial. Am J Respir Crit Care Med, 2020, 202(5): 681-689.
|
41. |
Rubinsky B. Irreversible electroporation in medicine. Technol Cancer Res Treat, 2007, 6(4): 255-260.
|
42. |
Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. J Membr Biol, 1972, 10(3): 279-290.
|
43. |
Crowley JM. Electrical breakdown of bimolecular lipid membranes as an electromechanical instability. Biophys J, 1973, 13(7): 711-724.
|
44. |
Zimmermann U, Pilwat G, Riemann F. Dielectric breakdown of cell membranes. Biophys J, 1974, 14(11): 881-899.
|
45. |
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng, 2005, 33(2): 223-231.
|
46. |
Miller L, Leor J, Rubinsky B. Cancer cells ablation with irreversible electroporation. Technol Cancer Res Treat, 2005, 4(6): 699-705.
|
47. |
Rubinsky B, Onik G, Mikus P. Irreversible electroporation: A new ablation modality-clinical implications. Technol Cancer Res Treat, 2007, 6(1): 37-48.
|
48. |
Ball C, Thomson KR, Kavnoudias H. Irreversible electroporation: A new challenge in "out of operating theater" anesthesia. Anesth Analg, 2010, 110(5): 1305-1309.
|
49. |
Thomson KR, Cheung W, Ellis SJ, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol, 2011, 22(5): 611-621.
|
50. |
Niessen C, Jung EM, Schreyer AG, et al. Palliative treatment of presacral recurrence of endometrial cancer using irreversible electroporation: A case report. J Med Case Rep, 2013, 7: 128.
|
51. |
Sun JH, Zhu TY, Chen XH, et al. In vivo evaluation of bronchial injury of irreversible electroporation in a porcine lung ablation model by using laboratory, pathological, and CT findings. Int J Clin Exp Pathol, 2018, 11(3): 1273-1280.
|
52. |
Sciurba FC, Dransfield MT, Kim V, et al. Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOx. BMJ Open Respir Res, 2023, 10(1): e001710.
|
53. |
Gompelmann D, Heussel CP, Eberhardt R, et al. Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema. Respiration, 2012, 83(5): 400-406.
|
54. |
Herth FJ, Ernst A, Baker KM, et al. Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema. Int J Chron Obstruct Pulmon Dis, 2012, 7: 397-405.
|
55. |
Snell G, Herth FJ, Hopkins P, et al. Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema. Eur Respir J, 2012, 39(6): 1326-1333.
|
56. |
Gompelmann D, Eberhardt R, Ernst A, et al. The localized inflammatory response to bronchoscopic thermal vapor ablation. Respiration, 2013, 86(4): 324-331.
|
57. |
Gompelmann D, Eberhardt R, Schuhmann M, et al. Lung volume reduction with vapor ablation in the presence of incomplete fissures: 12-month results from the STEP-UP randomized controlled study. Respiration, 2016, 92(6): 397-403.
|
58. |
Denner DR, Doeing DC, Hogarth DK, et al. Airway inflammation after bronchial thermoplasty for severe asthma. Ann Am Thorac Soc, 2015, 12(9): 1302-1309.
|
59. |
Pretolani M, Bergqvist A, Thabut G, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. J Allergy Clin Immunol, 2017, 139(4): 1176-1185.
|
60. |
Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2018, 13: 2163-2172.
|
61. |
Koegelenberg CF, Theron J, Slebos DJ, et al. Antimuscarinic bronchodilator response retained after bronchoscopic vagal denervation in chronic obstructive pulmonary disease patients. Respiration, 2016, 92(1): 58-60.
|
62. |
Kistemaker LE, Slebos DJ, Meurs H, et al. Anti-inflammatory effects of targeted lung denervation in patients with COPD. Eur Respir J, 2015, 46(5): 1489-1492.
|
63. |
Slebos DJ, Shah PL, Herth FJF, et al. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am J Respir Crit Care Med, 2019, 200(12): 1477-1486.
|
64. |
Hartman JE, Herth FJF, Shah P, et al. Computed tomographic airway morphology after targeted lung denervation treatment in COPD. Respir Med, 2023, 206: 107059.
|
65. |
Herth FJF, Slebos DJ, Criner GJ, et al. Endoscopic lung volume reduction: An expert panel recommendation: Update 2019. Respiration, 2019, 97(6): 548-557.
|